Kakisis J D, Abir F, Liapis C D, Sumpio B E
Department of Vascular Surgery, Yale University School of Medicine, New Haven, CT 06510, U.S.A.
Eur J Vasc Endovasc Surg. 2003 Jun;25(6):493-504. doi: 10.1053/ejvs.2002.1851.
to summarize existing evidence regarding the benefits and the risks of all available interventional and medical means aimed at cardiac risk reduction in patients undergoing vascular surgery.
review of the literature.
a critical review of all studies examining the impact of various prophylactic cardiac maneuvers on perioperative outcome following vascular surgery was performed. Overall mortality, cardiac mortality and myocardial infarction rate were used as the outcome measures.
coronary artery bypass grafting is associated with a 60% decrease in perioperative mortality in patients undergoing vascular surgery, but in most of the cases this decrease does not outweigh the combined risk of the cardiac and the subsequent noncardiac vascular procedure. Data supporting the cardioprotective effect of percutaneous transluminal angioplasty in the perioperative setting are insufficient. beta-blockade has been shown to decrease perioperative mortality and cardiac morbidity in both high-risk (strong evidence) and low-risk (weak evidence) patients.
coronary revascularization is rarely indicated to simply get the patient through vascular surgery and should be reserved for patients who would need it irrespective of the scheduled vascular procedure. Among all available pharmacological agents, including beta-blockers, alpha-agonists, calcium channel blockers and nitrates, only beta-blockers have been proven to reduce the cardiac risk of vascular surgery.
总结现有证据,以探讨针对接受血管手术患者降低心脏风险的所有可用介入和药物治疗手段的益处与风险。
文献综述。
对所有研究进行批判性回顾,这些研究考察了各种预防性心脏干预措施对血管手术后围手术期结局的影响。将总死亡率、心脏死亡率和心肌梗死发生率用作结局指标。
冠状动脉旁路移植术与接受血管手术患者围手术期死亡率降低60%相关,但在大多数情况下,这种降低并不超过心脏手术及随后非心脏血管手术的综合风险。支持经皮腔内血管成形术在围手术期具有心脏保护作用的数据不足。β受体阻滞剂已被证明可降低高危(有力证据)和低危(较弱证据)患者的围手术期死亡率和心脏发病率。
冠状动脉血运重建很少仅用于使患者顺利通过血管手术,应仅用于那些无论是否进行预定血管手术都需要该治疗的患者。在所有可用的药物制剂中,包括β受体阻滞剂、α激动剂、钙通道阻滞剂和硝酸盐,只有β受体阻滞剂已被证明可降低血管手术的心脏风险。